What is Northwest Biotherapeutics Revenue per Share?
Northwest Biotherapeutics's revenue per share for the
three
months ended in Jun. 2024 was £0.00.
Northwest Biotherapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was £0.00.
Warning Sign:
Northwest Biotherapeutics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Northwest Biotherapeutics was -100.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 2.00% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -25.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Northwest Biotherapeutics's Revenue per Share or its related term are showing as below:
During the past 13 years, Northwest Biotherapeutics's highest 3-Year average Revenue Per Share Growth Rate was 180.20% per year. The lowest was -88.80% per year. And the median was -27.20% per year.
LTS:0K95's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
Northwest Biotherapeutics Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Northwest Biotherapeutics's Revenue per Share
For the Biotechnology subindustry, Northwest Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's PS Ratio falls into.
Northwest Biotherapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Northwest Biotherapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (LTS:0K95) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Northwest Biotherapeutics Revenue per Share Related Terms
Thank you for viewing the detailed overview of Northwest Biotherapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0K95 has been successfully added to your 